2022
ESG REPORT 
HIGHLIGHTS

FY2022 ESG REPORT HIGHLIGHTS
Our vision is to create a better and healthier every day for every 
woman. We aim to deliver innovation, expand access, and empower 
women and girls to make informed choices about their healthcare 
so that they can achieve their promise. Our focus areas include:
We are a global healthcare company 
committed to improving women's health. 
Women’s Health
We believe women are the foundation of a healthier world and we know that 
women need more choices when it comes to their healthcare. We continue to 
build on our strengths in reproductive health and fertility as we assemble a suite 
of health options that help address areas of high unmet need for women.
Biosimilars
$481 million
Established Brands
$3.874 billion
REVENUE 
SPLIT IN 20221
$6.2B 
total revenue 
Women’s Health
$1.673 billion 
We focus on three key areas to achieve 
our vision of a better and healthier every 
day for every woman:
Biosimilars
Biosimilars, which are approved by regulators as being highly similar to their 
referenced biologic medicines, are used to treat a range of serious conditions and 
can reduce costs compared to biologics. We aim to improve health care 
economies and access to treatment by providing high-quality biosimilar 
medicines to health care systems, providers, and patients.
Established Brands
Our Established Brands include well-known products, which generally are beyond 
market exclusivity, across therapeutic areas including respiratory, cardiovascular, 
dermatology, non-opioid pain, and more. We are seizing new opportunities to 
bring these important treatments to patients who need them.
About us
2
1 Please see our Annual Report / 10-K to learn more about our revenue in 2022.

FY2022 ESG REPORT HIGHLIGHTS
8
We are a global healthcare company dedicating to advancing the health of women. Our research and 
development and business development activities focus on four cornerstones of women’s health: contraception, 
fertility, maternal and peripartum conditions, and conditions unique to women. 
2022 Highlights
Social: Her Equity
transactions completed 
(Two completed in 2021, five completed 
in 2022 and one completed in early 
20231) advancing our vision to provide 
solutions for unmet health needs.
Innovation and access 
73
pledged toward reducing 
unintended pregnancies and 
empowering women and girls 
through our Her Plan is Her Power 
three-year initiative (launched in 2023). 
1 This data reflects information from after 2022. All other information in this report reflects data from Spin on June 2, 2021 through December 31, 2022.
2 Total donations calculated using WAC cost, as of Jan 14, 2022.
of biosimilars 
donated to eligible 
patients across the 
United States.2
lowest-income countries 
eligible for the Her Promise Access 
Initiative, our effort to provide 100 
million women with contraceptive 
options in support of our FP2030 goal. 
$30M
$18.9M
25% 
increase of our addressable spend with 
diverse suppliers by 2025, from a 2021 
baseline. We will use leading metrics to 
measure our economic impact and job 
creation in our communities.
Supplier diversity and engagement
48% 
increased diverse spend 
over 2021 actuals, achieving 
this goal in 2022.
90%
feel diversity is
valued at Organon
feel they are proud to 
work for Organon
89%
86%
feel they can be their 
authentic selves at work
85%
feel their work gives 
them a sense of personal 
accomplishment
53%
of employees 
are women
Among Organon employees
13
global grants – from countries, such 
as Dominican Republic, South Korea, 
Germany, and Thailand – that will provide 
resources to help women and girls 
reduce unplanned pregnancies and 
take control of their reproductive health. 
Community engagement
2 
gender-focused grants tailored 
to the needs of women and girl 
refugees in Ukraine and Poland. 
3

FY2022 ESG REPORT HIGHLIGHTS
1 MT CO2e = metric ton of carbon dioxide equivalent.
2 Scope 3 emissions are the result of activities from assets not owned or controlled by the reporting organization, but GHG emissions 
associated with the value chain.
3 This is an initial estimate of Scope 3 GHG emissions in 2022 based on modelling aligned with The Greenhouse Gas Protocol (GHG 
Protocol) Corporate Value Chain (Scope 3) Accounting and Reporting Standard (also referred to as the Scope 3 Standard). The GHG 
emissions model may be subject to further revision which may result in adjustments to the estimated emissions for 2022 in the future. 
Scope 1 and 2 emissions are based on reported emissions, not modeled emissions, and therefore are not directly comparable to Scope 3 
emissions.
4 May not add up to total due to rounding. 
5 The energy usage of our (commercial) Fleet (which is also scope 1) is not included in this overview. For the GHG emissions associated 
with our Fleet see our Scope 1 and 2 GHG emission data. 
6 Bloomberg, Women Reach 32% of S&P 500 Board Seats for the First Time, 2022, 
https://www.bloomberg.com/news/articles/2022-12-21/women-reach-32-of-s-p-500-board-seats-for-the-first-time.
We seek to reduce our environmental impact through the efficient use of energy, water, and materials in our operations.
Environmental: Her Planet
of our operational waste 
was reused, recycled, or 
otherwise used beneficially. 
of total Scope 32 GHG emissions.3, 4 reduction in total 
energy5 use throughout 
our six sites against the 
2020 baseline.
of our manufacturing sites 
have already invested in 
biodiversity projects either 
on or off site. 
2022 HIGHLIGHTS
reduction in Scope 1 and 2 
greenhouse gas emissions 
(GHG) emissions against the 
2020 baseline. 
Nearly 
70%
89%
66% 
3.4% 
1,029,000 MT CO2e1 
2.4% 
Our Board of Directors and Executive Leadership Team 
oversees ESG-related issues.
Governance: Her Trust
46%
12
66%
of our directors are 
women—recognized 
as the most gender-
diverse Board in the 
S&P 500.6
of our directors are from 
U.S. underrepresented 
racial and ethnic 
groups.
of our standing 
Board committees are 
chaired by women.
number of 
independent 
directors.
4

FY2022 ESG REPORT HIGHLIGHTS
We believe that by advancing the health of women, we advance the health of society. Our ESG strategy helps 
ensure we deliver on our corporate vision: A better and healthier every day for every woman. Our ESG priorities 
are embedded throughout our business, where we focus on the issues that matter most to our stakeholders, 
our company, and women around the world. 
Our Approach to ESG
Her Promise. Our Purpose. Here For her Health.
HER EQUITY
Address unmet health needs of 
women while helping to ensure 
sustainable access to our products 
and instill a culture of belonging for 
employees and business partners. 
HER PLANET
Aim to achieve net zero 
greenhouse gas (GHG) emissions 
and integrate water stewardship 
and circular economy principles 
into our business model.
HER TRUST
Help ensure strong Board 
oversight and elevate our 
commitment to transparency, 
ethics, integrity, compliance, 
privacy, and product quality. 
SOCIAL
ENVIRONMENT
GOVERNANCE 
Access to medicines and healthcare
Community engagement 
Diversity, equity, inclusion, and belonging (DEI&B) 
Employee health and safety 
Human capital
Innovation for women’s health 
Product safety and quality 
Air emissions 
Biodiversity
Climate change risks and resilience 
Energy usage 
GHG emissions
Waste management 
Water usage 
Board composition and practices
Ethics and compliance 
Ethical marketing practices
Fair competition and open markets 
Human rights 
Political contributions and public policy
Privacy and data security
Procurement and supply chain practices
Product labeling 
Tax 
5

FY2022 ESG REPORT HIGHLIGHTS
Our purpose is to help all women 
and girls achieve their promise 
through better health. We are 
working to achieve Her Promise 
through the following goals.
Our Goals 
Innovation in women’s health
Eight transactions completed or executed 
since 2021 that allow us to advance 
meaningfully toward our mission. 
2021
2022
20231
Two 
transactions
Five 
transactions
One 
transaction
We aim to redefine and harness innovation in 
women’s health by dedicating a majority of our 
pre-clinical and clinical development activity 
toward areas that address the unmet health 
needs of women and girls.
We will work with partners to expand access 
to treatment options that improve her health 
and help secure her promise.
We will search for potential solutions that 
can achieve a significant impact by improving 
care, diagnosis, quality of life, and health 
outcomes for women. 
Expanding access to medicines 
and healthcare
Working together with partners, we aim to 
prevent an estimated 120 million unintended 
pregnancies by 2030.
We plan to provide 100 million girls and 
women in low-and middle-income countries 
(LMICs) with affordable access to 
contraceptive options by 2030. 
We are working with health authorities to find 
ways to expand access to the JADA® system, a 
medical device intended to help control and 
treat abnormal postpartum uterine bleeding or 
hemorrhage when conservative management 
is warranted, to women around the world. 
Diversity, equity, inclusion 
and belonging
We aim to achieve balanced gender 
representation through all levels of the 
company globally by 2030.
To reach this goal, we strive to maintain our 
current global gender balance while increasing 
the number of women in mid- to senior 
leadership roles.3
43.45%
46.70%
2021
2022
99.5% 
gender pay equity in the United States, 
the United Kingdom, and Switzerland.
99.9% 
pay equity for non-White (incl. Black, 
Hispanic, and Asian employees) and 
White employees in the United States.
1  This data reflects information from after 2022. All other information in this report reflects data from Spin on June 2, 2021 through December 31, 2022.
2 Her Promise Access Initiative program began with Merck & Co in 2012.
3 Where and to the extent permitted by law.
We aim to achieve pay equity. 
We have completed pay equity studies 
conducted by external economic and legal 
experts in three of our largest markets (the 
United States, the United Kingdom, and 
Switzerland) and plan to conduct studies in 
these and additional markets in 2023, 
which, in total, account for approximately 
60% of our employees globally.
Our female representation in roles 
at director-level and above
47 million women provided with access to 
IMPLANON NXT™(etonogestrel implant) 
and we had helped prevent 57 million 
unintended pregnancies since the Her 
Promise Access Initiative program began.2
By the end of 2022
6
PROGRESS
PROGRESS
PROGRESS
PROGRESS

FY2022 ESG REPORT HIGHLIGHTS
OUR GOALS
Environmental Stewardship
By 2025, we aim to support the transition to a low-carbon 
economy, with an ambition to achieve net zero GHG emissions 
in our operations and through our supply chain.
We aim to reduce our Scope 1 and 2 GHG emissions by more than 25% from 
2020 levels. 1,2
Our goal is to have at least 70% of our supplier spend devoted to suppliers 
that have GHG emissions reduction programs.
We plan to characterize our Scope 3 GHG emissions and regularly update 
them to reflect our supply chain.
By 2050, we aim to integrate water stewardship and circular 
economy principles into our business models. 
2.3% reduction 
in water usage 
compared to 
2020 levels.
89% of our operational 
waste was reused, 
recycled, or otherwise 
used beneficially.
ACHIEVED 2022
3.4% reduction in 
Scope 1 and 2 GHG 
emissions against 
the 2020 baseline.
1 For our baseline, we assumed that fleet emissions for 2020 are the same as in 2022.
2 Biogenic emissions are included in our Scope 1 and 2 GHG emissions goal.
3 Otherwise used beneficially includes composting and incinerated with heat recovery.
.
We began reviewing our 
suppliers’ GHG emission 
reduction plans. We are 
evaluating supply chain risk 
management tools that 
will track, trend, and help 
develop our suppliers’ 
environmental sustainability.
We have made progress 
on our goal of characterizing 
Scope 3 GHG emissions by 
developing an initial estimate 
of Scope 3 GHG emissions in 
2022.
Montserr
at 
SemiBold
Our goal for biodiversity
By 2025
ACHIEVED 2022
PROGRESS
PROGRESS
We will be assessing all 
new products against 
the Sustainability 
Packaging Guidelines, 
which will drive 
recycled content, 
recyclability, and 
responsible sourcing.
7
We will plan to invest in projects that preserve and 
restore biodiversity at or near all Organon 
manufacturing facilities and major office locations.
Four out of six of our manufacturing sites 
have already invested in biodiversity 
projects either on or off site. 
By the end of 2023, all six sites 
will have reached this goal. 
In 2023, we will also plan to investigate 
biodiversity projects for our major 
office locations.
PROGRESS
Our ambition is to preserve and increase biodiversity 
at our locations and in our communities.
By 2050
By 2025:
We aim to reduce water usage in our operations by >5% from 2020 levels
Our goal is to have at least 70% of our supplier spend devoted to 
suppliers that have water reduction programs.
We plan to characterize the water usage in our value chain and regularly 
update it to reflect our value chain.
We aim to have 30% of our legacy packaging reviewed against the 
Sustainability Packaging Guidelines to identify opportunities to reduce 
our environmental impact. 
Our goal is that more than 80% of our sites’ operational waste will be 
reused, recycled, or otherwise used beneficially.3

FY2022 ESG REPORT HIGHLIGHTS
Select awards and recognition 
We became a signatory for the UN Women’s Empowerment Principles, which aim to advance gender equality.
2022 Comparably awards:
Best CEO
Best CEOs for Diversity
Best CEOs for Women
Best Company Compensation
Best Company Culture
Best Company for Diversity
Best Company for Women
Best Global Culture
Best HR Team
Best Operations Team
Bloomberg Gender-Equality Index
DE&I Best Practices Belonging Award                   
Happiest Employees
Newsweek Most Responsible Businesses
Prime Employers for Women Gold Award
OUR GOALS
8
We currently have the most gender-
diverse Board of Directors in the 
S&P 500,1  as well as one of the most 
diverse Boards in the healthcare 
industry. We aspire to maintain the 
expertise as well as the gender and 
racial diversity that characterizes our 
Board composition today.
We are committed to upholding the highest levels of ethics and 
integrity throughout our business.
In early 2023, MSCI upgraded Organon’s ESG 
rating to an A, driven largely by its assessment 
of our governance processes.
Nearly 70% of our directors 
are women. 
70%
66%
66% of our standing Board 
committees are chaired by women. 
PROGRESS
We aim to engage at least five new or existing suppliers in a 
development and mentorship program and increase addressable 
spend with diverse suppliers by 25%, from a 2021 baseline, by 2025.2
Our goals for supplier diversity and engagement
Organon increased diverse 
spend by 48% over 2021 actuals, 
achieving this goal in 2022.
Organon’s Chief Procurement 
Officer was recognized as one 
of the TOP 25 Diversity 
Change Leaders by Diversity 
Plus Magazine.
46% of our directors are from U.S. 
underrepresented racial and 
ethnic groups.
PROGRESS
1 Bloomberg, Women Reach 32% of S&P 500 Board Seats for the First Time, 2022, https://www.bloomberg.com/news/articles/2022-12-21/women-reach-32-of-s-p-500-board-seats-for-the-first-time.
2 Where and to the extent permitted by law.
About half have 
lived and worked 
outside the United 
States and bring 
their global 
perspective to our 
organization.
PROGRESS
Deliver on trust